Abstracts tagged "Systemic sclerosis"

Abstract Number: 1855 • ACR Convergence 2021
Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis
Yoshinobu Koyama¹, Yoshiharu Sato², Tatsuma Shoji², Soichiro Fuke¹, Takatsune Umayahara¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Pulmonary hypertension (PH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of current…
Abstract Number: 0400 • ACR Convergence 2021
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
John Pauling¹, Lesley Ann Saketkoo², Dinesh Khanna³, Christopher Denton⁴, Tracy Frech⁵, Ariane Herrick⁶, Laura Hummers⁷, Ami Shah⁸ and Robyn Domsic⁹, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ³University of Michigan, Ann Arbor, MI, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University of Utah, Salt Lake City, UT, ⁶University of Manchester, Salford, United Kingdom, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Kristina Clark¹, Eszter Csomor², Corrado Campochiaro³, Adam Taylor⁴, Yee Voan Teo², Katherine Nevin², Mary Morse², Voon Ong⁵, Emma Derrett-Smith⁶, Nicolas Wisniacki², Shaun Flint² and Christopher Denton⁷, ¹University College London, London, United Kingdom, ²GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ³Royal Free Hospital London, London, United Kingdom, ⁴GlaxoSmithKline, London, United Kingdom, ⁵University College London Medical School Royal Free Campus, London, United Kingdom, ⁶University College London Division of Medicine, London, United Kingdom, ⁷University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
Abstract Number: 0854 • ACR Convergence 2021
Confirmatory Factor Analysis of the Fatigue Assessment Instrument and Fatigue Severity Scale in Systemic Sclerosis
Alyssa Choi¹, Chelsea Rapoport², Erin Merz³, Marka Lyons⁴, Maureen Mayes⁵, Shervin Assassi⁶ and Vanessa Malcarne⁷, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, La Jolla, CA, ³Department of Psychology, California State University, Dominguez Hills, Carson, CA, ⁴Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶University of Texas McGovern Medical School at Houston, Houston, TX, ⁷SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA
Background/Purpose: Fatigue is a prevalent, debilitating symptom across chronic diseases that is difficult to treat and negatively impacts patients' quality of life. Patients with rheumatologic…
Abstract Number: 1374 • ACR Convergence 2021
A Deep Neural Network Classifier to Identify Inflammatory Systemic Sclerosis Patients from Histological Images
Yiwei Yuan¹, Robert Lafyatis², Johann Gudjonsson³, Dinesh Khanna⁴ and Michael Whitfield⁵, ¹Dartmouth College, Hanover, NH, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) patients can be divided into four molecular subsets (inflammatory, fibroproliferative, limited and normal-like) identifiable with gene expression in skin and peripheral…
Abstract Number: 1836 • ACR Convergence 2021
Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis
Julia Spierings¹, Svetlana Nihtyanova², Emma Derrett-Smith³, Kristina Clark², Jacob van Laar⁴, Voon Ong⁵ and Christopher Denton⁶, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University College London, Royal Free Campus, London, United Kingdom, ³University College London Division of Medicine, London, United Kingdom, ⁴University Medical Centre Utrecht, Utrecht, Netherlands, ⁵University College London Medical School Royal Free Campus, London, United Kingdom, ⁶University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Autologous haematopoietic stem cell transplantation (SCT) has emerged as an effective treatment for patients with severe diffuse systemic sclerosis (dcSSc) based upon the results…
Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar², Rebecca Ross², Christopher Denton³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
Abstract Number: 0547 • ACR Convergence 2021
Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis Results in Sustained Changes in Immunoregulatory T and NK Cells
Ross Penglase, Malini Visweswaran, John Zaunders, Laila Girgis, David Ma and John Moore, St Vincent's Hospital, Sydney, Australia
Background/Purpose: Autologous Haematopoietic Stem Cell Transplantation (AHSCT) is an effective treatment for severe systemic sclerosis (SSc). To date, mechanistic studies have indicated possible pro-regulatory and…
Abstract Number: 1001 • ACR Convergence 2021
Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Rajan Bhandari¹, Heetaek Yang², Noelle Kosarek³, Michael Whitfield⁴ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Geisel School of Medicine, Hanover, NH, ³Dartmouth Geisel School of Medicine, Hartford, VT, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Prior work demonstrates that macrophages (MØs) from patients with Systemic Sclerosis (SSc) produce fibrotic and pro-inflammatory mediators and that cocultured MØs and SSc fibroblasts…
Abstract Number: 1375 • ACR Convergence 2021
Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis
Nancy Maltez¹, Mianbo Wang², Georges Wells³, Peter Tugwell¹, Murray Baron⁴, Zora Marjanovic⁵, Pauline Lansiaux⁶, Dominique Farge⁶ and Marie Hudson⁷, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Jewish General Hospital, Montréal, QC, Canada, ⁵Hopital Saint-Antoine, Paris, France, ⁶8. Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France, Paris, France, ⁷McGill University, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a chronic disease characterized by vasculopathy, inflammation and fibrosis. Rheumatologists have limited options to effectively treat rapidly progressive disease. There…
Abstract Number: 1838 • ACR Convergence 2021
Further Construct Validation of the
Julia Spierings¹, Voon Ong² and Christopher Denton³, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University College London Medical School Royal Free Campus, London, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Evaluation of skin is central in clinical management of systemic sclerosis (SSc). Due to the COVID-19 pandemic remote consultations were widely implemented, which inevitably…
Abstract Number: 1857 • ACR Convergence 2021
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
Marco Di Battista¹, Saverio Vitali², Simone Barsotti³, Alessandra Della Rossa⁴, Valentina Dini⁵, Marco Romanelli⁵ and Marta Mosca³, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit - University of Pisa, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit - University of Pisa, Pisa, Italy, ⁵Dermatology Unit - University of Pisa, Pisa, Italy
Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0549 • ACR Convergence 2021
Upregulation of Prostanoid EP2 Receptors and Meditation of Treprostinil Anti-Proliferative Effects in Scleroderma Smooth Muscle Cells
Yongqing Wang¹, Nezam Altorok² and Bashar Kahaleh², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction leads to dysregulated vascular tone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].